Policy Applies to: Commercial and Medicare plans

Background: Pregabalin (Lyrica™) is an analog of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA), exhibits analgesic, anxiolytic and anticonvulsant activity. It is indicated for the management of neuropathic pain associated with diabetic peripheral neuropathy (DPN) and postherpetic neuralgia (PHN). It is also indicated for adjunctive treatment of adult patients with partial onset seizures and for the treatment of fibromyalgia. It is not indicated as monotherapy for partial onset seizures. Unlike other medications used for these indications, pregabalin is inactive at serotonin and dopamine receptors and does not inhibit dopamine, serotonin, or noradrenaline reuptake. Pregabalin is the first drug approved for use in the treatment of fibromyalgia.

The literature does not support the use of pregabalin for the treatment of generalized anxiety disorder and will not be covered to treat this condition.

Approval Criteria: When a benefit, coverage for pregabalin will be approved if members meet one of the following criteria:

1. The member has at least one claim for a medication used for the treatment of diabetes within the last year, OR
2. There is a claim for one antiviral medication used for the treatment of herpes zoster infection in the members' pharmacy profile within the last year, OR
3. There are claims for two antiepileptic drugs (AED) in the members' pharmacy profile within the last year, OR
4. There are claims for two tricyclic antidepressants (TCA) in the members' pharmacy profile within the last year, OR
5. There are claims for one AED and one TCA in the members' pharmacy profile within the last year.

Members who meet the criteria as outlined above will receive automatic authorization at the pharmacy without documentation of additional information. Claims will automatically adjudicate on-line, with no prior authorization required.

Members who do not meet this above criteria will require prior authorization. One of the following criteria would then need to be documented.
1. The member has a documented diagnosis of DPN, **OR**
2. The member has a documented diagnosis of PHN, **OR**
3. The member has a documented diagnosis of seizures: **AND** has tried and failed two AED, **OR**
4. The member has a documented diagnosis of unspecified neuropathic pain: **AND** has failed two other medications in the following classes: AED or TCA. **OR**
5. The member has a documented diagnosis of fibromyalgia as determined by clinical notes including, but not limited to, confirmation of widespread bilateral pain both above and below the waist for > 3 months duration **AND** the presence of at least 11 of 18 specific tender points **AND** documented fibromyalgia-related symptoms (e.g. fatigue, sleep disturbance, neurologic symptoms, and/or exercise intolerance). **AND**
6. The member has a documented trial and failure of at least one additional agent used to treat fibromyalgia (e.g. tricyclic agents, cyclobenzaprine, SSRI, tramadol).

**Authorization Duration**

If approved, up to a lifetime authorization may be granted.

**References:**


[Version 004 of J-300]
[Version 003 of J-300]
[Version 002 of J-300]
[Version 001 of J-300]
Pharmacy policies do not constitute medical advice, nor are they intended to govern physicians' prescribing or the practice of medicine. They are intended to reflect Highmark's coverage and reimbursement guidelines. Coverage may vary for individual members, based on the terms of the benefit contract.

Highmark retains the right to review and update its pharmacy policy at its sole discretion. These guidelines are the proprietary information of Highmark. Any sale, copying or dissemination of the pharmacy policies is prohibited; however, limited copying of pharmacy policies is permitted for individual use.